Caracterização do perfil de microvesículas cirdulantes em pacientes com policitemia vera

• Ano de defesa: 2023
• Autor(a) principal: Sousa, Milane Araújo de
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade do Estado do Amazonas; Brasil; UEA; PPGH -PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS APLICADAS À HEMATOLOGIA
• Palavras-chave em Português: Neoplasia mieloproliferativa; Microvesícula; Policitemia vera; Myeloproliferative neoplasm
• Link de acesso: https://ri.uea.edu.br/handle/riuea/2265

Polycythemia Vera (PV) is part of the group of myeloproliferative neoplasms (PMNs), in which it is characterized by an increase in erythrocyte mass. It is believed that VMs play an important role in the development of neoplasms and may be essential for understanding these pathologies. It has already been described that microvesicles (MVs) contribute to the development of PV with their greater procoagulant activity, increasing the risk of thrombotic complications. Objectives: To characterize the profile of circulating microvesicles in patients diagnosed with Polycythemia Vera treated at the Hospital Foundation for Hematology and Hemotherapy of Amazonas. Material and methods: Sixty-six individuals of both sexes were included and categorized into two groups: 33 patients with a conclusive diagnosis of Polycythemia Vera undergoing treatment and 33 healthy individuals for the control group. Clinical data were obtained from the patients' charts. Laboratory data were obtained from blood samples. Immunophenotypic characterization was performed on a CytoFlex S flow cytometer (Beckman Coulter) using the VM immunophenotyping protocol of the Integrated Group for Biomarker Research (GIPB) of the René Rachou Institute (IRR)-Fiocruz Minas. Results: There was a higher level of MVs CD34, CD13, CD33 (progenitor/myeloid), CD11c (dendritic cells), CD16, CD66b (neutrophils), CD3 (T Lymphocytes), CD19 (B Lymphocytes), CD56 (NK cells) , CD235a (erythrocytes) and CD51/61 (endothelial cells) in patients with PV. There were no significant levels of MVs in the groups of patients with and without thrombotic events. Higher levels of CD3 (lymphocytes) and CD51/61 (endothelial cells) MVs were identified in JAK2V617F+ patients with thrombotic events. Conclusion: In the analysis of the profile of MVs, higher levels of MVs were observed in patients with PV than in healthy individuals. It was also observed that JAK2V617F+ patients who have a history of thrombosis had higher levels of CD3 MVs (T lymphocytes) and CD51/61 (endothelial cells). in the pathogenesis of thrombosis. Future studies are essential to analyze VMs in the context of treatment, in addition to seeking to understand their role in the prognosis, as well as in the prothrombotic state of patients with PV.